Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

I want to enter information about my cancer and treatments

Matching Trials

For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.

  Clinical Trial Phase Eligible Participant Official Title Location Drugs in Trial Results
NCT03398655IIIPlatinum resistant ovarian cancer, excluding primary platinum refractoryA Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian CancerAL, AZ, CA, CT, FL, GA, IL, IN, KS, KY, LA, MD, MA, MI, NH, NJ, NM, NY, NC, ND, OH, OK, PA, SC, SD, TX, VT, WA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Ofranergene obadenovecVB-111Endothelin promoter-apoptotic receptor gene therapyClinical Trials
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT03632798IIIRecurrent ovarian cancerAvastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Chosen by Cancer Stem Cell Chemosensitivity Testing in the Management of Patients With Recurrent Platinum-Resistant or -Sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerMS, WVView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
DocetaxelTaxotereMicrotubule stabilizer/mitotic inhibitorApproved in Other Cancers
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
Liposomal doxorubicinPegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, DoxilTopoisomerase II inhibitorApproved in Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
TopotecanHycamptamine, Hycamtin, TOPOTopoisomerase I inhibitorApproved in Ovarian Cancer
NCT03949283IIIPlatinum resistant ovarian cancerStandard Chemotherapy Versus Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian CancerAZ, CA, LA, OH, OK, PA, WVView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
DocetaxelTaxotereMicrotubule stabilizer/mitotic inhibitorApproved in Other Cancers
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
Liposomal doxorubicinPegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, DoxilTopoisomerase II inhibitorApproved in Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
TopotecanHycamptamine, Hycamtin, TOPOTopoisomerase I inhibitorApproved in Ovarian Cancer
NCT03940196IIIRecurrent ovarian cancer, excluding primary platinum refractory (≤2 prior therapies for platinum resistant disease)ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian CancerAZ, CA, CO, FL, GA, IL, IA, KY, MD, MA, MN, MO, NE, NV, NJ, NC, OH, OR, PA, RI, SD, TX, VA, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
TTfieldsNovoTTF-100L(O)Microtubule destabilizer/mitotic inhibitorClinical Trials
NCT04209855IIIPlatinum resistant FRalpha+ high grade serous ovarian cancer, excluding primary platinum refractoryMIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha ExpressionAL, AK, AZ, CA, CO, CT, FL, GA, IL, IN, KY, LA, MD, MA, MI, MN, MO, MT, NV, NJ, NY, NC, OH, OK, OR, PA, RI, TN, TX, VA, WA, WVView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Mirvetuximab soravtansineM9346A-sulfo-SPDB-DM4, IMGN853, Anti-FOLR1-mab Maytansinoid ConjugateADC: anti-FOLR1 + microtubule destabilizer (DM4)Clinical Trials
NCT04296890IIIPlatinum resistant FRalpha+ ovarian cancer with prior bevacizumab; excluding primary platinum refractorySORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha ExpressionAZ, CA, CO, FL, GA, IL, IN, KS, KY, LA, MD, MA, MO, NV, NJ, NY, TN, TX, WA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Mirvetuximab soravtansineM9346A-sulfo-SPDB-DM4, IMGN853, Anti-FOLR1-mab Maytansinoid ConjugateADC: anti-FOLR1 + microtubule destabilizer (DM4)Clinical Trials
NCT04729387IIIPlatinum resistant or refractory gBRCA WT high grade serous or endometrioid ovarian cancerEPIK-O: A Phase III, Multi-center, Randomized (1:1), Open-label, Active-controlled, Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy, in Participants With no Germline BRCA Mutation Detected, Platinum-resistant or Refractory, High-grade Serous Ovarian CancerContact research study staffView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AlpelisibPI3K inhibitor BYL719, BYL719, phosphoinositide 3-Kinase inhibitor BYL719, PiqrayPI3K alpha inhibitorApproved in Other Cancers
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT04729608IIIPlatinum resistant high grade serous ovarian cancer, excluding primary platinum refractoryA Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian CancerNJ, OHView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AVB-S6-500AVB-500GAS6 antagonistClinical Trials
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT02502266II/IIIPlatinum resistant or refractory high grade serous or endometrioid ovarian cancer or germline BRCA1/2-mutated ovarian cancerA Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)AL, AK, AR, CA, CO, CT, DE, DC, FL, GA, ID, IL, IN, IA, KS, KY, LA, ME, MD, MA, MI, MN, MS, MO, MT, NE, NV, NH, NJ, NM, NY, NC, ND, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, VA, WA, WV, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CediranibAZD2171, Cediranib maleate, RecentinVEGFR1-3 kinase inhibitorClinical Trials
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT02839707II/IIIPlatinum resistant or refractory ovarian cancerA Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian CancerAK, AZ, AR, CA, CO, CT, DE, DC, FL, GA, HI, ID, IL, IN, IA, KS, KY, LA, ME, MD, MA, MI, MN, MS, MO, MT, NE, NV, NH, NJ, NM, NY, NC, ND, OH, OK, OR, PA, RI, SC, SD, TN, TX, VA, WA, WV, WI, WYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer
Liposomal doxorubicinPegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, DoxilTopoisomerase II inhibitorApproved in Ovarian Cancer
NCT02312245IIRecurrent ovarian cancerAvatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube CancersAZ, FL, MNView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
Liposomal doxorubicinPegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, DoxilTopoisomerase II inhibitorApproved in Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
TopotecanHycamptamine, Hycamtin, TOPOTopoisomerase I inhibitorApproved in Ovarian Cancer
NCT02272998IIAdvanced solid tumors with FGFR1-4, PDGFRa, Kit, RET, FLT3, or Abl1 alterationsPhase II Study of Ponatinib for Advanced Cancers With Genomic Alterations in Fibroblastic Growth Factor Receptor (FGFR) and Other Genomic Targets (KIT, PDGFRá, RET FLT3, ABL1)OHView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Ponatinibmultitargeted tyrosine kinase inhibitor AP24534, Iclusig, AP24534Multi-targeted kinase inhibitorApproved in Other Cancers
NCT02079740IIAdvanced solid tumors with KRAS or NRAS mutations (in expansion)An Open Label, Two-Part, Phase Ib/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor Trametinib and the BCL2-Family Inhibitor Navitoclax (ABT-263) in Combination in Subjects With KRAS or NRAS Mutation-Positive Advanced Solid TumorsMAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NavitoclaxABT-263, A-855071.0, Bcl-2 Family Protein Inhibitor ABT-263Bcl-2, Bcl-XL, and Bcl-w inhibitorClinical Trials
TrametinibMekinist, MEK Inhibitor GSK1120212, JTP-74057, GSK1120212, TMT212MEK1/2 inhibitorApproved in Other Cancers
NCT02568267IIAdvanced solid tumors with NTRK1/2/3, ROS1, or ALK rearrangementsAn Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene RearrangementsAZ, CA, CO, FL, IL, MD, MA, MN, NV, NY, NC, OH, TX, UT, VA, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
EntrectinibRXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, RozlytrekALK, TRK, ROS1 kinase inhibitorApproved in Other Cancers
NCT02693535IIOvarian expansion for CDKN2A loss or MUT, or high TMB, or ERBB2/ERBB3 AMP, MUT or over-expression or Advanced solid tumors with molecular alterations in ALK, ATM, BRAF, BRAFV600E/D/K/R, BRCA1/2, CDK4, CDK6, CDKN2A, CSF1R, KIT, MET, MLH1, MSH2, MSH6, mTOR, PALB2, PDGFR, PDGFRB, PMS2, POLD1, POLE, RAF-1, RET, ROS1, TSC1/2, VEGFR, high MSI, high TMBTargeted Agent and Profiling Utilization Registry (TAPUR) StudyAL, AZ, CA, FL, GA, HI, IL, IN, ME, MI, NE, NH, NC, ND, OK, OR, PA, SD, TX, UT, VA, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AbemaciclibBemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, VerzenioCDK4/6 inhibitorApproved in Other Cancers
AfatinibBIBW 2992 MA2, Gilotrif, Afatinib dimaleateEGFR, HER2, HER4 kinase inhibitorApproved in Other Cancers
CobimetinibXL518, GDC-0973, CotellicMEK1 inhibitorApproved in Other Cancers
Crizotinibc-met/HGFR tyrosine kinase inhibitor PF-02341066, PF-02341066, Xalkoric-Met and ALK kinase inhibitorApproved in Other Cancers
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
PalbociclibPD-0332991, PD0332991, IbranceCDK4/6 inhibitorApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
PertuzumabPerjeta, monoclonal antibody 2C4, rhuMAb2C4HER2 dimerization inhibitorApproved in Other Cancers
RegorafanibBAY73-4506, multikinase inhibitor BAY 73-4506, StivargaMulti-targeted RTK inhibitorApproved in Other Cancers
SunitinibSutent, Sunitinib malateVEGFR2, PDGFR-beta, c-Kit, and FLT3 kinase inhibitApproved in Other Cancers
TalazoparibMDV3800, BMN-673, Talazoparib Tosylate, TalzennaPARP inhibitorApproved in Other Cancers
TemsirolimusTorisel, CCI-779mTOR inhibitorApproved in Other Cancers
TrastuzumabHerceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal AntibodyHER2 antagonistApproved in Other Cancers
VemurafenibRO5185426, PLX4032, ZelborafBRAF kinase inhibitorApproved in Other Cancers
NCT02465060IIExpansion for BRAF V600E or V600K, or advanced solid tumors with alterations in cKIT, CDK4/6 AMP, EGFR, MET, MET AMP, mTOR, NTRK1-3, PTEN, TSC1/2 or PTEN lossMolecular Analysis for Therapy Choice (MATCH)AL, AK, AZ, AR, CA, CO, CT, DE, DC, FL, GA, HI, ID, IL, IN, IA, KS, KY, LA, ME, MD, MA, MI, MN, MS, MO, MT, NE, NV, NH, NJ, NM, NY, NC, ND, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, VA, WA, WV, WI, WYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AfatinibBIBW 2992 MA2, Gilotrif, Afatinib dimaleateEGFR, HER2, HER4 kinase inhibitorApproved in Other Cancers
CopanlisibBAY 80-6946, PI3K inhibitor BAY 80-6946pan-PI3K inhibitorApproved in Other Cancers
Crizotinibc-met/HGFR tyrosine kinase inhibitor PF-02341066, PF-02341066, Xalkoric-Met and ALK kinase inhibitorApproved in Other Cancers
DabrafenibGSK-2118436A, BRAF inhibitor GSK2118436, GSK2118436, TafinlarBRAF kinase inhibitorApproved in Other Cancers
LarotrectinibTrk inhibitor LOXO-101, LOXO-101, Vitrakvipan-Trk kinase inhibitorApproved in Other Cancers
OsimertinibMereletinib, EGFR inhibitor AZD9291, AZD9291, TagrissoEGFR kinase inhibitorApproved in Other Cancers
PalbociclibPD-0332991, PD0332991, IbranceCDK4/6 inhibitorApproved in Other Cancers
SapanisertibINK128, TORC1/2 Inhibitor INK128, TORC1/2 Inhibitor MLN0128, MLN0128, TAK-228TORC1/2 kinase inhibitorClinical Trials
SunitinibSutent, Sunitinib malateVEGFR2, PDGFR-beta, c-Kit, and FLT3 kinase inhibitApproved in Other Cancers
TrametinibMekinist, MEK Inhibitor GSK1120212, JTP-74057, GSK1120212, TMT212MEK1/2 inhibitorApproved in Other Cancers
NCT02628067IIAdvanced solid tumors with high MSI or high TMBA Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)CA, FL, MD, MA, NJ, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT02554812IIAdvanced solid tumors (in ovarian expansion) - intratumoral injectionA Phase 1b/2 Open-Label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (MSB0010718C) In Combination With Other Cancer Immunotherapies In Patients With Advanced MalignanciesCA, DC, FL, IA, KY, MI, NY, PA, RI, SD, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AvelumabAnti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, BavencioBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
PD-0360324anti–M-CSF mAb PD-0360324, anti-CSF1 monoclonal antibody PD-0360324CSF1R antagonist and tumor-associated macrophage inhibitorClinical Trials
NCT02873962IIPartially platinum sensitive or resistant ovarian cancer (for combo w/ rucaparib patients have to be BRCA WT and have no prior PARP inhibitor)A Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal CancerMAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
RucaparibRubraca, CO-338, PF 01367338, AG-014699PARP inhibitorApproved in Ovarian Cancer
NCT01851369IIGranulosa cell ovarian cancerA Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and LymphomasMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
MethoxyamineTRC102Base excision repair inhibitorClinical Trials
TemozolomideTemodal, Temodar, MethazolastoneDNA damaging agentApproved in Other Cancers
NCT02364713IIPlatinum resistant, refractory or persistent ovarian cancer (no measurable disease outside the peritoneal cavity)MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal CancerAZ, FL, MNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
MV-NISoncolytic measles virus encoding thyroidal sodium iodide symporterInduces immune response and tumor cell lysisClinical Trials
NCT02675829IIAdvanced solid tumors with HER2 amplificationA Phase 2 Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant CancersNYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Trastuzumab emtansinetrastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansineADC: anti-HER2 + microtubule destabilizer (DM1)Approved in Other Cancers
NCT02834013IIAdvanced ovarian small cell cancerDART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare TumorsAL, AK, AZ, AR, CA, CO, CT, DE, DC, FL, GA, HI, ID, IL, IN, IA, KS, KY, LA, ME, MD, MA, MI, MN, MS, MO, MT, NE, NV, NH, NJ, NM, NY, NC, ND, OH, OK, OR, PA, SC, SD, TN, TX, UT, VT, VA, WA, WV, WI, WYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT02843165IIAdvanced solid tumors with lesion treatable with radiation therapyRandomized Phase II Study of Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation Therapy in Advanced Metastatic DiseaseCAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
Radiation TherapyRadiotherapy, Irradiation
NCT03026062IIPlatinum resistant or refractory clear cell ovarian cancerRandomized Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab Administered in Combination Versus Sequentially in Recurrent Platinum-Resistant Epithelial Ovarian CancerTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
Tremelimumabanti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, TicilimumabBlocks CTLA-4 inhibition of T cellsClinical Trials
NCT03113487IIPlatinum resistant or refractory ovarian cancerP53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerCAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
p53MVAModified Vaccinia Virus Ankara Vaccine Expressing p53, MVAp53Immune response against p53 tumor antigenClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03212274IIAdvanced solid tumors with IDH1 or IDH2 mutations, no prior PARP inhibitorA Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid TumorsCA, CT, FL, KS, KY, MD, MA, MO, NH, NJ, NY, NC, OH, OK, PA, TN, TX, WIView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT03284385IIAdvanced solid tumors with SETD2 deficiencyA Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor MalignanciesCA, IL, KS, MD, MA, MI, NY, PA, TN, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AdavosertibWEE1 inhibitor AZD1775, MK1775, AZD1775WEE1 inhibitorClinical Trials
NCT03310879IIAdvanced solid tumors with CCND1/2/3 alterations or CDK4/6 amplificationsA Phase II Study of the CDK4/6 Inhibitor Abemaciclib in Patients With Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6MAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AbemaciclibBemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, VerzenioCDK4/6 inhibitorApproved in Other Cancers
NCT03355976IIRecurrent clear cell ovarian cancerBrUOG 354: A Phase II Randomized Trial of Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell CarcinomasRIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03428802IIAdvanced solid tumors with POLE, POLD, or BRCA1/2 mutationsA Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic InstabilityNJView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03462342IIRecurrent ovarian cancer; excluding primary platinum refractoryCombination ATR and PARP Inhibitor (CAPRI) Trial With AZD 6738 and Olaparib in Recurrent Ovarian CancerMD, MA, PAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CeralasertibATR kinase inhibitor AZD6738, AZD6738ATR kinase inhibitorClinical Trials
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT03570619IIAdvanced solid tumors with CDK12 alterationsIMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 MutationsCA, FL, MD, MI, MO, NYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03579316IIRecurrent ovarian cancer with progression on or after prior PARP inhibitorEFFORT: Efficacy of AZD1775 in Parp Resistance; A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Women With Ovarian Cancer Who Have Progressed During PARP InhibitionMA, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AdavosertibWEE1 inhibitor AZD1775, MK1775, AZD1775WEE1 inhibitorClinical Trials
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT03610490IIRecurrent or refractory high grade serous ovarian cancer or carcinosarcomaClinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor TypesTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
MDA-TILautologous tumor-infiltrating lymphocytes MDA-TILAnti-tumor immune responseClinical Trials
NCT03651271IIRecurrent ovarian cancer with dMMR, high MSI or high TMBAn Exploratory Study of Nivolumab With or Without Ipilimumab According to the Percentage of Tumoral CD8 Cells in Participants With Advanced Metastatic CancerCA, NY, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03668119IIAdvanced solid tumors with high TMBA Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)CA, CO, MN, NY, NC, OR, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03587311IIPlatinum resistant or refractory mesothelin+ high grade serous or endometroid ovarian cancerA Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian CancerCA, FL, IL, KS, MI, NJ, OH, TN, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Anetumab ravtansineAnti-mesothelin Antibody-Drug Conjugate BAY 94-9343, BAY 94-9343ADC: anti-Mesothelin + microtubule destabilizer (DM4)Clinical Trials
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT03682289IIAdvanced solid tumors with ARID1A (except clear cell) or ATM alterationsPhase II Trial of AZD6738 Alone and in Combination With Olaparib in Patients With Selected Solid Tumor MalignanciesCAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CeralasertibATR kinase inhibitor AZD6738, AZD6738ATR kinase inhibitorClinical Trials
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT03693014IIAdvanced solid tumors with dMMR, high TMB or high MSI with limited progression on checkpoint inhibitor treatmentA Phase II Trial of Hypofractionated Radiotherapy in Patients With Limited Progression on Immune Checkpoint BlockadeCT, NJ, NY, PAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
Radiation TherapyRadiotherapy, Irradiation
NCT03732950IIRecurrent ovarian cancerA Phase II Study of Pembrolizumab Monotherapy in Recurrent Ovarian Cancer of the Immunoreactive Subtype Determined by NanoString Gene Expression ProfilingCA, MNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03673124IIRecurrent low grade serous ovarian cancerA Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube or PeritoneumCA, FL, GA, IL, IN, MN, NH, NJ, NM, OH, OK, PA, RI, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
LetrozoleFemaraAromatase inhibitorNCCN Guidelines for Ovarian Cancer
RibociclibKisqali, CDK4/6 Inhibitor LEE011, LEE011, KisqaliCDK4/6 inhibitorApproved in Other Cancers
NCT03742895IIAdvanced solid tumors without BRCA1/2 mutations, with Homologous Recombination Repair gene mutations (e.g., ATM, PALB2, RAD51D) or HRD+, no prior PARP inhibitorA Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced CancerAZ, CA, CO, GA, KY, MD, MA, MI, NE, NJ, NY, OK, PA, SD, UT, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT03657043IIPlatinum resistant ovarian cancer with prior bevacizumab, excluding primary platinum refractory (≤1 prior therapy for platinum resistant disease)Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense RegimenCA, CO, FL, GA, KS, MI, MO, NJ, NY, NC, OH, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Tisotumab vedotinHuMax-TF-ADC, TF-011-MMAEADC: anti-TF + microtubule destabilizer (MMAE)Clinical Trials
NCT03797326IIAdvanced solid tumors (in ovarian expansion)A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects With Selected Solid Tumors (LEAP-005)CA, FL, NJ, NY, SD, TN, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
LenvatinibE7080, ER-203492-00, Lenvima, MK-7902VEGFR1-3 kinase inhibitorApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03868423IIAdvanced solid tumors with ALK or ROS1 activating genomic aberrationsPhase II Study of Brigatinib for Advanced Solid Cancers Harboring Genomic Alterations in ALK (Excluding Lung) and ROS1 OncogenesOHView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BrigatinibAP26113, AlunbrigALK and EGFR kinase inhibitorApproved in Other Cancers
NCT03697304IIAdvanced solid tumors with prior anti-PD-1/PD-L1 AbAn Open-label, Phase II, Platform Trial Evaluating Safety and Efficacy of Multiple BI 754091 Anti-PD-1 Based Combination Regimens in PD-(L)1 naïve and PD-(L)1 Pretreated Patient Populations With Advanced and/or Metastatic Solid Tumours Who Have Had at Least One Line of Systemic TherapyCA, FL, IN, KY, OK, TN, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BI 754111Blocks LAG-3 inhibition of T cellsClinical Trials
Ezabenlimabanti-PD-1 monoclonal antibody BI 754091, BI 754091Blocks PD-L1/2 inhibition of T cellsClinical Trials
NCT03878849IIRecurrent ovarian cancerPhase II, Prospective Open Label, Single Arm Study to Investigate Anti-tumor Effect and Tolerability of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP®MAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
StenoparibPARP/Tankyrase inhibitor 2X-121, E7449, 2X-121PARP inhibitorClinical Trials
NCT03909152IIRecurrent PR+ low grade serous or granulosa cell ovarian cancerBasket Study of the Oral Progesterone Antagonist Onapristone ER (Apristor) in Women With Progesterone Receptor Positive (PR+) Recurrent Granulosa Cell Tumor, Low Grade Serous Ovarian Cancer or Endometrioid Endometrial CancerNJ, NYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Onapristone ERextended-release onapristonePR antagonist that blocks PR activation and the associated expression of PR-responsive genes
NCT03911557IIAdvanced solid tumors with moderate/high TMBPhase 2 Investigation of MEDI4736 (Durvalumab) and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid TumorsKYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
Tremelimumabanti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, TicilimumabBlocks CTLA-4 inhibition of T cellsClinical Trials
NCT03822117IIAdvanced solid tumors with FGFR1-3 gene mutations, fusions or rearrangementsA Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)AZ, CA, FL, IL, IN, IA, KS, LA, MA, MN, NV, NH, NY, NC, OK, SC, TN, TX, VA, WA, WV, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PemigatinibFGFR inhibitor INCB054828, INCB054828, PemazyreFGFR1-3 inhibitorApproved in Other Cancers
NCT03907475IIAdvanced solid tumors (with tumor amenable to skin biopsy)DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody MEDI4736 (Durvalumab) in Combination With Chemotherapy in Patients With Advanced Solid TumorsMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CapecitabineXeloda, CAPERNA processing and thymidylate synthase inhibitorNCCN Guidelines for Ovarian Cancer
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
Liposomal doxorubicinPegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, DoxilTopoisomerase II inhibitorApproved in Ovarian Cancer
nab-PaclitaxelPaclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007Microtubule stabilizer/mitotic inhibitorNCCN Guidelines for Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT03935893IIAdvanced solid tumorsA Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients With Advanced Solid CancersPAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AldesleukinProleukinIL-2 receptor agonistApproved in Other Cancers
Autologous TILsImmune response against tumor-associated antigensClinical Trials
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitorApproved in Other Cancers
NCT02710253IIAdvanced solid tumors (amenable to radiation therapy)Phase II Trial of Salvage Radiation Therapy to Induce Systemic Disease Regression After Progression on Systemic ImmunotherapyTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Radiation TherapyRadiotherapy, Irradiation
NCT03449108IIRecurrent high grade ovarian cancer or carcinosarcomaClinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor TypesTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AldesleukinProleukinIL-2 receptor agonistApproved in Other Cancers
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitorApproved in Other Cancers
LN-145-S1Autologous Tumor Infiltrating Lymphocytes LN-145-S1, PD-1 selected TIL therapyImmune response against tumor-associated antigensClinical Trials
NCT03994796IIAdvanced solid tumors with brain metastases and NTRK, ROS1, CDK pathway or PI3K pathway alterationsGenomically-Guided Treatment Trial in Brain MetastasesAK, AZ, AR, CA, CO, CT, FL, GA, ID, IL, IA, KY, LA, MA, MI, MN, MS, MO, MT, NE, NH, NJ, NM, NY, NC, OH, OK, OR, PA, TX, UT, VT, VA, WA, WI, WYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AbemaciclibBemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, VerzenioCDK4/6 inhibitorApproved in Other Cancers
EntrectinibRXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, RozlytrekALK, TRK, ROS1 kinase inhibitorApproved in Other Cancers
PaxalisibRG7666, PI3K inhibitor GDC-0084, GDC-0084PI3K/mTOR inhibitor
NCT03872427IIAdvanced solid tumors with NF1, KEAP1/NRF2 or LKB1 mutationsA Phase II Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 HCl in Patients With NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant TumorsAL, FL, KS, KY, MD, MA, MO, NY, NC, OH, PA, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Telaglenastatglutaminase inhibitor CB-839, CD-839Glutaminase inhibitorClinical Trials
NCT04003623IIAdvanced solid tumors with FGFR mutations or translocationsA Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumors Harboring Activating FGFR Mutations or Translocations (FIGHT-208)CA, FL, HI, IL, MD, NJ, OH, SD, TX, UTView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PemigatinibFGFR inhibitor INCB054828, INCB054828, PemazyreFGFR1-3 inhibitorApproved in Other Cancers
NCT04055649IIPlatinum resistant or refractory ovarian cancerPhase II Study of ONC201 Plus Weekly Paclitaxel in Patients With Platinum-Resistant Refractory or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerMIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
ONC201AKT/ERK inhibitor ONC201, TIC10AKT and ERK kinase inhibitorClinical Trials
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT04056910IIAdvanced solid tumors with IDH1 mutationsPhase II Study of IDH1 Inhibitor Ivosidenib and Nivolumab in IDH1 Mutant Gliomas and Advanced Solid TumorsPAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
IvosidenibAG-120IDH1 inhibitorApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT04083976IIAdvanced solid tumors with FGFR mutations or gene fusionsA Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene AlterationsAZ, CO, FL, GA, ME, MA, MI, NJ, NY, NC, OH, PA, TN, TX, WA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Erdafitinibpan-FGFR tyrosine kinase inhibitor JNJ-42756493pan-FGFR kinase inhibitorApproved in Other Cancers
NCT04123366IIAdvanced BRCA WT solid tumors with mutations in homologous repair (HRR) genes (i.e. BRIP1, PALB2) or HRD+ patients, no prior PARP inhibitor or checkpoint inhibitorA Phase 2 Study of Olaparib in Combination With Pembrolizumab in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced CancerAL, AZ, CA, CO, FL, GA, KY, NJ, NY, OH, OK, TX, UT, VA, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT04171219IIAdvanced solid tumorsA Phase 2 Basket Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPP), Administered in Combination With Pembrolizumab in Patients With Advanced Solid CancersTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
TalabostatBXCL701, Val-boro-Pro, talabostat mesylate, PT100Dipeptidyl peptidase inhibitorClinical Trials
NCT04171700IIAdvanced solid tumors with mutations in BARD1, BRIP1, FANCA, NBN, RAD51, RAD51B, RAD51C or RAD51D, no prior PARP inhibitorA Phase 2 Multicenter, Open-label Study of Rucaparib as Treatment for Solid Tumors Associated With Deleterious Mutations in Homologous Recombination Repair GenesCA, FL, IL, IA, MA, MN, NY, OH, OK, PA, TN, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
RucaparibRubraca, CO-338, PF 01367338, AG-014699PARP inhibitorApproved in Ovarian Cancer
NCT04172597IIAdvanced solid tumors with EGFR or ERBB2 activating mutationsA Phase 2 Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced MalignanciesCAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PoziotinibNOV120101, pan-HER kinase inhibitor HM781-36BEGFR, HER2, HER4 kinase inhibitor
NCT04233567IIAdvanced solid tumors with FGFR alterationsA Phase II Study of Oral Infigratinib in Adult Patients With Advanced or Metastatic Solid Tumors With FGFR1-3 Gene Fusions or Other FGFR Genetic AlterationsOHView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Infigratinibpan FGFR Kinase Inhibitor BGJ398, BGJ398pan-FGFR kinase inhibitorClinical Trials
NCT04374630IIPlatinum resistant ovarian cancer; must either have received or be ineligible for prior bevacizumab and/or PARP inhibitor (≤1 prior therapy for platinum resistant disease)An Open Label Randomized Active Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients With Platinum-Resistant Ovarian CancerAZ, AR, CA, HI, IL, KY, MA, NJ, NM, NY, OH, PA, RI, TX, VA, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AfuresertibGSK2110183Akt inhibitorClinical Trials
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT04383210IIAdvanced solid tumors with a NRG1 gene fusionCRESTONE: A Phase 2 Study of Seribantumab in Adult Patients With Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid TumorsAZ, CA, CO, FL, GA, IL, MA, MI, MN, MO, NY, NC, TN, TX, UT, VA, WA, WIView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
SeribantumabSAR256212, MM-121ERBB3 antagonistClinical Trials
NCT04393454IIAdvanced solid tumors with dMMR, after prior immunotherapyPhase II Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After ImmunotherapyNYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
SirolimusRapamycin, RapamunemTOR inhibitorApproved in Other Indications
NCT04449549IIRecurrent rare tumorsRapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and PaclitaxelMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NilotinibAMN 107, TasignaBcr-abl, c-Kit, and PDGFR kinase inhibitorApproved in Other Cancers
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT04469764IIRecurrent ovarian cancer with CCND1-3 or CDK4/6 AMP or CDKN2A alterationsAn Open Label Phase II Study of the Efficacy and Safety of Abemaciclib, a Cyclin Dependent Kinase (CDK4/6) Inhibitor in Selected Patients With Recurrent Ovarian or Endometrial CancerCAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AbemaciclibBemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, VerzenioCDK4/6 inhibitorApproved in Other Cancers
AnastrozoleArimidexAromatase inhibitor
LetrozoleFemaraAromatase inhibitorNCCN Guidelines for Ovarian Cancer
NCT04482309IIAdvanced HER2+ solid tumorsA Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)CA, IL, IN, MA, MI, NJ, NY, NC, TN, TX, VA, WAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Trastuzumab deruxtecanT-Dxd, DS-8201, fam-trastuzumab deruxtecan-nxki, ADC DS-8201a, anti-HER2 antibody-drug conjugate DS-8201a, anti-HER2 ADC DS-8201a, DS-8201aADC: anti-HER2 + topoisomerase I inhibitor (Dxd)Approved in Other Cancers
NCT04488003IIAdvanced solid tumors with atypical BRAF or MEK alterationsA Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF AlterationsAZ, DE, FL, MA, MN, NC, TX, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
UlixertinibBVD-523, ERK inhibitor BVD-523ERK inhibitorClinical Trials
NCT04504942IIAdvanced CCR5+ solid tumors - subcutaneous injection of leronlimab with standard-of-care chemotherapyBasket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid TumorsCAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Leronlimabanti-CCR5 monoclonal antibody PRO 140Modulates the tumor microenvironment and blocks tumor angiogenesisClinical Trials
NCT04534283IIAdvanced solid tumors with alterations in BRAF, RAF1, MEK1/2, ERK1/2 or NF1A Phase 2 Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib for Patients Whose Tumors Harbor Pathogenic Alterations in BRAF, RAF1, MEK1/2, ERK1/2, and NF1.INView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AbemaciclibBemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, VerzenioCDK4/6 inhibitorApproved in Other Cancers
LY3214996ERK inhibitorClinical Trials
NCT04564027IIAdvanced solid tumors with ATM mutationsA Modular Phase 2a Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE)CA, FL, IN, MD, MI, NV, NY, PA, SCView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CeralasertibATR kinase inhibitor AZD6738, AZD6738ATR kinase inhibitorClinical Trials
NCT04592653IIRecurrent ovarian cancerClinical and Immunologic Activity of ALKS 4230 on Tumor Microenvironment in Solid Tumor Patients - ARTISTRY-3TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Nemvaleukin alfaALKS4230, Nemvaleukin, intermediate-affinity interleukin-2 receptor agonist ALKS 4230IL-2R beta and gamma agonistClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT04589845IIAdvanced solid tumors with alterations in AKT1/2/3, ALK, ERBB2, MDM2, NTRK1/2/3, PIK3CA (multiple mutations), ROS1 or with high TMBTumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform TrialAL, AZ, CA, CO, DE, FL, GA, ID, IL, IN, ME, MI, MN, MO, NV, NH, NJ, NM, NY, NC, OH, OR, PA, SC, TN, TX, WA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AlectinibAF802, anaplastic lymphoma kinase inhibitor CH5424802, Alecensa, ALK inhibitor CH5424802ALK kinase inhibitorApproved in Other Cancers
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
EntrectinibRXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, RozlytrekALK, TRK, ROS1 kinase inhibitorApproved in Other Cancers
IdasanutlinRO5503781, RG7388, MDM2 antagonist RO5503781MDM2 antagonist
InavolisibRG6114, GDC-0077PI3K alpha inhibitorClinical Trials
IpatasertibGDC-0068, Akt Inhibitor GDC-0068, RG7440pan-AKT inhibitorClinical Trials
Trastuzumab emtansinetrastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansineADC: anti-HER2 + microtubule destabilizer (DM1)Approved in Other Cancers
NCT04625270IIRecurrent low grade serous ovarian cancer with a KRAS mutationA Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)AZ, AR, CT, FL, IL, KS, MN, MO, NM, NY, OH, OK, OR, TN, TX, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DefactinibVS-6063, PF-04554878, PF-04554878FAK inhibitorClinical Trials
VS-6766CKI27, RO5126766, Raf/MEK dual kinase inhibitor RO5126766, CH5126766RAF and MEK inhibitorClinical Trials
NCT04632992IIAdvanced solid tumors with alterations in AKT1/2/3, ALK, ERBB2, PIK3CA, PTEN, ROS1 or with high TMB or high MSIMyTACTIC: An Open-Label Phase II Study Evaluating Targeted Therapies in Patients Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of ResponseAZ, CA, CT, FL, ID, LA, MI, MO, MT, NE, NJ, NY, OH, OR, TN, TX, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AlectinibAF802, anaplastic lymphoma kinase inhibitor CH5424802, Alecensa, ALK inhibitor CH5424802ALK kinase inhibitorApproved in Other Cancers
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
EntrectinibRXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, RozlytrekALK, TRK, ROS1 kinase inhibitorApproved in Other Cancers
InavolisibRG6114, GDC-0077PI3K alpha inhibitorClinical Trials
IpatasertibGDC-0068, Akt Inhibitor GDC-0068, RG7440pan-AKT inhibitorClinical Trials
PertuzumabPerjeta, monoclonal antibody 2C4, rhuMAb2C4HER2 dimerization inhibitorApproved in Other Cancers
TrastuzumabHerceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal AntibodyHER2 antagonistApproved in Other Cancers
Trastuzumab emtansinetrastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansineADC: anti-HER2 + microtubule destabilizer (DM1)Approved in Other Cancers
TucatinibIrbinitinib, ONT-380HER2 kinase inhibitorApproved in Other Cancers
NCT04639219IIAdvanced solid tumors with ERBB2 MUTA Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for the Treatment of Unresectable and/or Metastatic Solid Tumors Harboring HER2 Activating Mutations Regardless of Tumor HistologyCA, IL, IN, MA, MI, NY, TX, VA, WAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Trastuzumab deruxtecanT-Dxd, DS-8201, fam-trastuzumab deruxtecan-nxki, ADC DS-8201a, anti-HER2 antibody-drug conjugate DS-8201a, anti-HER2 ADC DS-8201a, DS-8201aADC: anti-HER2 + topoisomerase I inhibitor (Dxd)Approved in Other Cancers
NCT04644315IIAdvanced ALK+ solid tumors (excluding I1171X, G1202R, V1180L)A Phase II, Open-Label, Single Arm Decentralized Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid TumorsCA